Clinical Trial Update: Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravitreal aflibercept to prevent proliferative vitreoretinopathy after retinal detachment repair.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Vitreoretinopathy
• Retinal Detachment

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: M. Ali Khan, MD | Conditions: Retinal Detachment With Multiple Breaks, Unspecified Eye, Proliferative Vitreoretinopathy | Phase 2 | Status: UNKNOWN